{"name":"Alar Pharmaceuticals Inc.","slug":"alar-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"Alar Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for various medical conditions. The company has a pipeline of four drugs, with one already marketed and others in early stages of clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"ALA-1000","genericName":"ALA-1000","slug":"ala-1000","indication":"Other","status":"phase_1"},{"name":"ALA-3000","genericName":"ALA-3000","slug":"ala-3000","indication":"Other","status":"phase_1"},{"name":"buprenorphine sublingual film","genericName":"buprenorphine sublingual film","slug":"buprenorphine-sublingual-film","indication":"Other","status":"marketed"},{"name":"escitalopram, sertraline, duloxetine or venlafaxine XR","genericName":"escitalopram, sertraline, duloxetine or venlafaxine XR","slug":"escitalopram-sertraline-duloxetine-or-venlafaxine-xr","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ALA-1000","genericName":"ALA-1000","slug":"ala-1000","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALA-3000","genericName":"ALA-3000","slug":"ala-3000","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"buprenorphine sublingual film","genericName":"buprenorphine sublingual film","slug":"buprenorphine-sublingual-film","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"escitalopram, sertraline, duloxetine or venlafaxine XR","genericName":"escitalopram, sertraline, duloxetine or venlafaxine XR","slug":"escitalopram-sertraline-duloxetine-or-venlafaxine-xr","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNeTBCVVdTOUNDWl9IV3Y5dzU4azJCaXF0NEM1VmtYU3IwT2QyRnAzQmdQRGYwQ1FYWm44Nk9kVWdUNEg2Y2J0bWVUdGdtMFVpd0k1bkVuY3MzRGtFQWxCVWhtajFQb19NZVc5S1NSMXJmTHV5aVBJRmk0dmpDU192OENmdDNSamdOQThoLTZHWldqaDRZQzB3cjFlZzZLVkpHNmgzQVRHSm9Va3ZwcWNTRUdTaUh1dmxJejNCSWEwTXhKM3ZzZzgzTzM3Y1B3ZmlGLXhzQnBEZkIzclhh?oc=5","date":"2026-04-07","type":"trial","source":"BioPharma APAC","summary":"Alar Pharmaceuticals Reports Positive Phase 1 Results For ALA 3000 In Treatment Resistant Depression - BioPharma APAC","headline":"Alar Pharmaceuticals Reports Positive Phase 1 Results For ALA 3000 In Treatment Resistant Depression","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE5WNVpUWUZsYUtZTVhnNUlpdGF4bkREdVpXdDBOczR0ZVljVDN1dDF3aHRGaGpfWlh5dHAyN0VQQ0FhYUZzaFpwb0tEVWhrWUhwRE93VHZaWGZhZ1F6eEZleng3RDRqdw?oc=5","date":"2026-04-01","type":"pipeline","source":"GuruFocus","summary":"Stock List: Research Stocks from Around the World - GuruFocus","headline":"Stock List: Research Stocks from Around the World","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQWm5sQTRqM0IzZXpWdGdHZG1oOGxOOFpzdGFwemhMd3plczBnX0RHemxmVUVwSjFnbUJtOWdLclgzSlI4b2V5bmZmUzJpVHkxY1lKQUx0eGNKQ0w5TjMzNE9zaG5BNTVTa21wUnBzUkZ5bE5aWnVfZDA5SloxWkVHZ05EQWR4UENQSEdXUzRHaVRDRy1JNjVUS2YtMEt5R0tDd2Q1cGY2cGI4VHFuZENjNVBWYWFmYnE0bnZoelpQcmx5YlJSYjR1Szln?oc=5","date":"2023-10-11","type":"pipeline","source":"PR Newswire","summary":"Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals - PR Newswire","headline":"Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":3,"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}